KDMN News and Press, Kadmon Holdings Inc. From 11/11/19

KD025 Achieved ORRs of 64% with KD025 200 mg QD and 67% with KD025 200 mg BID Conference Call Today at 5:00 p.m. Eastern Time NEW YORK / ACCESSWIRE / November 11, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) today announced positive topline results from the planned interim analysis...

Kadmon (NYSE: KDMN ): Q3 GAAP EPS of -$0.49 misses by $0.27 . More news on: Kadmon Holdings, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2019. "Following the completion of enrollment in our registration trial of KD025 in cGVHD in August 2019,...

NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced a strategic partnership with BioNova Pharmaceuticals Ltd. (BioNova) to form a joint venture to exclusively develop and commercialize KD025 for the treatment of graft-versus-host disease (GVHD) ...

Insurance company versus big pharma - whose money is it anyway? Humana Inc. (HUM), a $39 billion health insurance company, accuses Teva Pharmaceutical Industries (TEVA), an $8 billion company, and a few other generic drug makers, of playing ugly in the generic drugs market. In a 610-page c...

The FDA approves Kadmon Holdings' (NYSE: KDMN ) Clovique (trientine hydrochloride capsules, USP), a room-temperature-stable branded generic product used to treat Wilson's disease , a rare inherited disorder characterized by the buildup of copper in the body. More news on: Kadmon Holding...

Product Offers Room Temperature Stability, Improving Convenience for Patients NEW YORK, NY / ACCESSWIRE / October 21, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved CLOVIQUE™ (Trientine Hydrochloride Capsule...

NEW YORK, NY / ACCESSWIRE / October 3, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the Company has entered into a transaction to divest approximately 1.4 million shares of MeiraGTx Holdings plc stock (MGTX). The transaction has been completed. Kadmon intends to use half of...

Kadmon Holdings (NYSE: KDMN ) inks an agreement with Cantor Fitzgerald for the at-the-market sale of up to $50M of its common stock. Cantor will earn a 3% commission for its efforts. More news on: Kadmon Holdings, Inc., Healthcare stocks news, Stocks on the move, Read more ...

NEW YORK, NY / ACCESSWIRE / September 17, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved its generic Trientine Hydrochloride Capsules USP, 250 mg. Trientine hydrochloride is used for the treatment of Wilson's dis...